Predictive Value of VO2peak in Adult Congenital Heart Disease in Comparison with Heart Failure with Reduced Ejection Fraction

Andrea Soares,Lauren Park,Emily Mansour,Elena Deych,Alyssa Puritz,Min Zhao,Chao Cao,Andrew R Coggan,Philip M Barger,Randi Foraker,Susan B Racette,Linda R. Peterson
DOI: https://doi.org/10.1101/2024.10.11.24315308
2024-10-13
Abstract:BACKGROUND: Peak oxygen consumption (VO2peak) is used to predict outcomes and the timing of transplantation in patients with heart failure with reduced ejection fraction (HFrEF); VO2peak also has predictive utility in patients with adult congenital heart disease (ACHD). However, the predictive value of a given VO2peak in patients with ACHD compared to those with HFrEF, especially after adjustment for age and sex, is not clear. METHODS: To address this, we performed a longitudinal cohort study comparing patients with ACHD to patients with HFrEF. The ACHD and HFrEF cohorts were matched for sex and age (+/- 10 y). VO2peak tests were conducted between 1993 and 2012. Events were defined as death, cardiac transplantation, or left ventricular assist device placement. Outcome data were obtained via electronic medical record, Social Security Death Index, and phone interview. Cox proportional-hazard regressions were used to evaluate relationships of event-free survival with predictor variables. RESULTS: Patients with ACHD (N=137) and HFrEF (N=137) with a median follow-up time of 14.5 (13.4-15.6) y in the ACHD cohort and 19 (14.8-21.1) y in the HFrEF cohort. Higher VO2peak was associated with lower risk for a cardiac outcome, independent of age and sex, in both ACHD (HR 0.89, 95% CI 0.83-0.96, P=0.002) and HFrEF (HR 0.85, 95% CI 0.81-0.89, P <0.001Male sex was associated with greater risk of a cardiac outcome (P=0.001) in ACHD (HR 3.34) and HFrEF (HR 1.83). After multivariable adjustment (that included age, sex, and VO2peak) having ACHD conferred a 66% lower risk of a cardiovascular event compared to a HFrEF diagnosis (HR 0.34, 95% CI 0.22-0.53, P<0.001). CONCLUSIONS: VO2peak independently predicts event-free survival among adults with ACHD or HFrEF and has clinical utility in the outpatient setting. Patients with ACHD, however, have a better prognosis for any given VO2peak compared to those with HFrEF.
What problem does this paper attempt to address?
The paper attempts to address the issue of evaluating the predictive value of peak oxygen uptake (V̇O2peak) in adult congenital heart disease (ACHD) patients and comparing it with patients with heart failure with reduced ejection fraction (HFrEF). Specifically, the study aims to explore the following aspects: 1. **Predictive value of V̇O2peak**: The researchers aim to verify whether V̇O2peak can independently predict event-free survival (i.e., no death, heart transplantation, or left ventricular assist device implantation) in ACHD patients and compare it with HFrEF patients. 2. **Predictive value adjusted for age and gender**: The researchers also want to understand whether the predictive value of V̇O2peak in ACHD patients remains significant after adjusting for age and gender. 3. **Comparison between ACHD and HFrEF**: The researchers aim to compare event-free survival at the same V̇O2peak levels between ACHD and HFrEF patients through age- and gender-matched cohort studies to determine if ACHD patients have a better prognosis. 4. **Other influencing factors**: The study also explores the impact of factors such as gender, body mass index, and medication use on event-free survival, particularly the differences between ACHD and HFrEF patients. Through these research objectives, the authors hope to provide more specific guidance for clinicians, especially in determining the timing of treatment and transplant evaluation for ACHD patients, and how to utilize V̇O2peak as an important indicator.